Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
  • Primary Care
  • Patient/Physician Communication
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.